ProCE Banner Activity

Phase II Smart Start: Ibrutinib, Lenalidomide, and Rituximab + Chemotherapy in Newly Diagnosed Non-GCB DLBCL

Slideset Download
Conference Coverage
In patients with non-GCB DLBCL, the use of RLI followed by RLI plus chemotherapy produced high response rates and prolonged survival times that compared favorably with historical results.

Released: June 11, 2019

Expiration: June 09, 2020

No longer available for credit.

Share

Provided by

Provided by the USF Health
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Astellas Seattle Genetics

Bayer Healthcare Pharma

Blueprint Medicines

Celgene

Novartis Pharmaceuticals Corporation

Puma Biotechnology, Inc.

Taiho Oncology Inc

Tesaro